The relation between arterial hypertension and COVID-19 as well as the impact of antihypertensive drugs, such as renin–angiotensin–aldosterone system (RAAS) blockers, on SARS-CoV-2 infection and disease severity persist as two debatable topics since the beginning of the pandemic [13, 14]. The gene discussed is REN; the disease is COVID-19.